Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jan 22;13:189–198. doi: 10.2147/OPTH.S191588

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Badawi. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Secondary efficacy end points – questionnaire results.

Notes: The mean (± SD) values for the subject responses are presented for the Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire (A), the Ocular Surface Disease Index (OSDI) questionnaire (B), and the Symptom Assessment in Dry eye (SANDE) questionnaire (C). Baseline assessments (indicated by open circles) were conducted prior to TearCare^® treatment at study initiation (Day 0) and at Month 7. Significant improvements in the change from baseline in mean scores (decreases in the score from baseline Day 0) are noted with the P-values for each panel.

Secondary efficacy end points – questionnaire results.

Notes: The mean (± SD) values for the subject responses are presented for the Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire (A), the Ocular Surface Disease Index (OSDI) questionnaire (B), and the Symptom Assessment in Dry eye (SANDE) questionnaire (C). Baseline assessments (indicated by open circles) were conducted prior to TearCare^® treatment at study initiation (Day 0) and at Month 7. Significant improvements in the change from baseline in mean scores (decreases in the score from baseline Day 0) are noted with the P-values for each panel.